高リン血症治療薬の世界市場予測

Inkwood Researchが発行した調査報告書(INKW709080)
◆英語タイトル:Global Hyperphosphatemia Drug Market Forecast 2017-2025
◆商品コード:INKW709080
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2017年6月24日
◆ページ数:145
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

Inkwood Research社が出版した本調査レポートでは、高リン血症治療薬の世界市場について調査・分析し、高リン血症治療薬の世界市場動向、市場予測、セグメント別分析、主要地域別分析(アメリカ市場、ヨーロッパ市場、アジア市場)、世界市場規模、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

KEY FINDINGSThe global hyperphosphatemia drugs market is expected to grow at a CAGR of 15.95 % during the forecast period of 2017-2025. The market is expected to be worth $8647 million by the year 2025. Increasing prevalence of chronic diseases, unmet medical needs, a high proportion of the elderly population and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market.

MARKET INSIGHTS
The market segmentation is done on the basis of the formulation. The various types of phosphate binders include calcium-based phosphate binders, aluminum-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders. Of these, the Calcium-based phosphate binder’s held the largest market share of 54.75% in 2016 and is expected to continue its dominance during the forecast period. The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients. In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.

REGIONAL INSIGHTS
The hyperphosphatemia drugs market in North America is expected to hold the largest share by the end of the forecast period due to changing dietary habits, increasing osteoporosis cases and a rising aging population in this region. The Europe hyperphosphatemia drugs market is also fast growing at a CAGR of 15.38%. However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of 18.74% during the forecast period.

COMPETITIVE INSIGHTS
The major companies in the hyperphosphatemia drugs market include, Johnson And Johnson, Amag Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, DSM Biotech Pharmacal , Ultragenyx, Fermenta Biotech Ltd, Pfizer Inc., Bruno Pharmaceutical Spa, Roche Diagnostics Corporation, Vifor Pharma, Sanofi R.H. Moore Drug Co., Shire, and Fresenius Medical Care.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. NORTH AMERICA IS THE GLOBAL LEADER FOR HYPERPHOSPHATEMIA DRUGS MARKET
3.2.2. CHINA IS LARGEST HEALTHCARE DRUGS AND EQUIPMENT MARKET IN ASIA-PACIFIC REGION
3.2.3. IRON-BASED HYPERPHOSPHATEMIA ARE A GAME CHANGER
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. GROWING PREVALENCE OF CHRONIC DISEASES
4.1.2. UNMET MEDICAL NEEDS
4.1.3. HIGH PROPORTION OF ELDERLY PEOPLE
4.1.4. RISE IN PUBLIC AWARENESS
4.2. RESTRAINTS
4.2.1. LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION (FDA)
4.2.2. GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
4.3. OPPORTUNITIES
4.3.1. ASIA PACIFIC REGIONS ARE EXPECTED TO PROPEL THE MARKET GROWTH
4.4. CHALLENGES
4.4.1. NON-ADHERENCE TO TREATMENT REGIMENS
4.4.2. SIDE EFFECTS OF DRUGS
4.4.3. LIMITED AVAILABILITY OF DRUGS
4.4.4. USE OF ADVANCED DIALYSIS TECHNIQUES
5. MARKET SEGMENTATION
5.1. MARKET BY FORMULATION
5.1.1. CALCIUM-BASED PHOSPHATE BINDERS
5.1.2. ALUMINUM-BASED PHOSPHATE BINDERS
5.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS
5.1.4. IRON-BASED PHOSPHATE BINDERS
5.1.5. OTHER PHOSPHATE BINDERS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. BARGAINING POWER OF BUYERS
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. THREAT OF SUBSTITUTE PRODUCT
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. OPPORTUNITY MATRIX
6.3. KEY BUYING CRITERIA
6.3.1. APPLICATION
6.3.2. PRICING
6.3.3. EFFECTIVENESS
6.3.4. AVAILABILITY
6.4. STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. ROE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. AUSTRALIA
7.3.5. ROAPAC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AMERICA
7.4.3. REST OF AFRICA
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
8.2.1. CASE STUDIES: TOP COMPETITIVE MOVES
9. COMPANY PROFILE
9.1. AMAG PHARMACEUTICALS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC ANALYSIS
9.2. JOHNSON AND JOHNSON
9.2.1. COMPANY OVERVIEW
9.2.2. SCOT ANALYSIS
9.2.3. STRATEGIC ANALYSIS
9.3. CIPLA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. KERYX BIOPHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVES
9.4.3. SCOT ANALYSIS
9.5. DSM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. BIOTECH PHARMACAL
9.6.1. OVERVIEW
9.6.2. STRATEGIC INITIATIVES
9.6.3. PRODUCTS PORTFOLIO
9.6.4. SCOT ANALYSIS
9.7. SUN PHARM INC
9.7.1. OVERVIEW
9.7.2. STRATEGIC INITIATIVE
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC ANALYSIS
9.8. ZERIA PHARMACEUTICAL
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC ANALYSIS
9.9. ULTRAGENYX
9.9.1. OVERVIEW
9.9.2. SCOT ANALYSIS
9.9.3. STRATEGIC ANALYSIS
9.10. BRUNO FARMACEUTICI SPA
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. FERMENTA BIOTECH LTD
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC ANALYSIS
9.12. PFIZER INC.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.13. ROCHE DIAGNOSTICS CORPORATION
9.13.1. OVERVIEW
9.13.2. STRATEGIC INITIATIVES
9.13.3. SCOT ANALYSIS
9.13.4. PRODUCT PORTFOLIO
9.13.5. STRATEGIC ANALYSIS
9.14. R.H. MOORE DRUG CO.
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT
9.14.4. STRATEGIC ANALYSIS
9.15. VIFOR PHARMA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT
9.15.4. STRATEGIC ANALYSIS
9.16. SANOFI
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC ANALYSIS
9.17. SHIRE
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC ANALYSIS
9.18. FRESENIUS MEDICAL CARE
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC ANALYSIS

TABLE LIST
TABLE # 1 GLOBAL HYPERPHOSPHATEMIA DRUG MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
TABLE # 3 GLOBAL PREVALENCE OF DIABETES 2015 AND 2035 (MILLIONS)
TABLE # 4 WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)
TABLE # 5 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE # 6 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 7 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 8 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 9 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 10 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 11 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 12 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
TABLE # 13 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
TABLE # 14 ASIA-PACIFICHYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
TABLE # 15 PER CAPITA CONSUMPTION OF DAIRY PRODUCTS IN AUSTRALIA
TABLE # 16 REST OF THE WORLD HYPERPHOSPHATEMIADRUGS MARKET 2017-2025($ MILLION)

FIGURE LIST
FIGURE # 1 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE # 2 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
FIGURE # 3 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 4 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 5 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 6 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 7 GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 8 PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET
FIGURE # 9 INVESTMENT PREPOSITION ACROSS REGIONS 2017-2025
FIGURE # 10 MARKET SHARE OF ANALYSIS OF KEY PLAYERS 2016 (%)
FIGURE # 11 UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 12 CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 13 UK HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 14 FRANCEHYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 15 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 16 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 17 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 18 ROE HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 19 AGE WISE DISTRIBUTION OF INDIAN POPULATION
FIGURE # 20 INDIA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 21 CHINA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 22 JAPAN HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 23 NUMBER OF FRACTURES DUE TO OSTEOPOROSIS AND OSTEOPENIA ($ MILLION)
FIGURE # 24 AUSTRALIA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 25 ROAPAC HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 26 REST OF THE WORLD GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 27 LATIN AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 28 MENA HYPERPHOSPHATEMIADRUGS MARKET 2017-2025($ MILLION)
FIGURE # 29 REST OF AFRICA GLOBAL HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)



【レポートのキーワード】

高リン血症治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 高リン血症治療薬の世界市場予測(Global Hyperphosphatemia Drug Market Forecast 2017-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆